<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01866072</url>
  </required_header>
  <id_info>
    <org_study_id>EC/01/13/455</org_study_id>
    <nct_id>NCT01866072</nct_id>
  </id_info>
  <brief_title>Evaluation of Role of Transient Elastography (Fibroscan) in Differentiating Patients of Acute Severe Viral Hepatitis and Acute on Chronic Liver Failure</brief_title>
  <acronym>ACLF</acronym>
  <official_title>A Prospective Evaluation of the Role of Transient Elastography (Fibroscan) in Differentiating Patients of Acute Severe Viral Hepatitis and Acute on Chronic Liver Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sir Ganga Ram Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sir Ganga Ram Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Transient elastography is novel non-invasive method for assessment of hepatic fibrosis in&#xD;
      patients with chronic liver disease, by measuring liver stiffness. Transient elastography is&#xD;
      a user friendly technique that can be easily performed at bedside or in outpatient clinic&#xD;
      with immediate results and good reproducibility.&#xD;
&#xD;
      Liver stiffness values ranges from 2.5 to 75 kPa with lower values &lt;6kPa suggest no fibrosis&#xD;
      where as higher values above 14kPa suggests cirrhosis. In the present study the investigators&#xD;
      hypothesis that the investigators can differentiate ACLF and acute severe viral hepatitis&#xD;
      based on fibroscan as patients with underlying fibrosis with superadded inflammation would&#xD;
      have higher fibroscan value than when patient have only inflammation with no underlying&#xD;
      fibrosis and hence the investigators can avoid unnecessary test in such subgroup.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Transient elastography is a novel non-invasive method that for the assessment of hepatic&#xD;
      fibrosis in patients with chronic liver diseases, by measuring liver stiffness.&#xD;
&#xD;
      Acute on chronic liver failure: acute hepatic insult manifesting as jaundice and&#xD;
      coagulopathy, complicated within 4 weeks by ascites and/or encephalopathy in patients with&#xD;
      previously diagnosed or undiagnosed chronic liver disease.&#xD;
&#xD;
      Acute severe hepatitis: Acute severe hepatitis which is characterized by serum bilirubin &gt; or&#xD;
      = 10.0 mg/dL and international normalized ratio (INR) &gt; or = 1.5.&#xD;
&#xD;
      Patients with acute severe viral hepatitis or acute on chronic liver failure will be enrolled&#xD;
      in this prospective study after taking informed written consent. All patients will be&#xD;
      evaluated at baseline as per standard protocol which include evaluation of etiology of&#xD;
      disease and tests to exclude underlying liver disease which includes ultrasound/computed&#xD;
      tomography and if necessary upper gastrointestinal endoscopy and liver biopsy if imaging&#xD;
      shows any signs of underlying liver disease. the patients will be followed up for 1 month,&#xD;
      all patients will undergo Fibroscan at the time of admission and thereafter at 1week and 4th&#xD;
      week .&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">January 2014</completion_date>
  <primary_completion_date type="Anticipated">November 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Fibroscan value at admission</measure>
    <time_frame>1st Day</time_frame>
    <description>The patient enrolled will undergo fibroscan procedure and baseline fibroscan values will be measured at the time of admission.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fibroscan value at week 1</measure>
    <time_frame>1st week</time_frame>
    <description>2nd fibroscan will be done at week 1 from date of admission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibroscan value at week 4</measure>
    <time_frame>4th week</time_frame>
    <description>3rd Fibroscan will be done at 4th week from date of admission.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Acute Severe Viral Hepatitis</condition>
  <condition>Acute on Chronic Liver Failure</condition>
  <arm_group>
    <arm_group_label>AVH</arm_group_label>
    <description>AVH: Patients with Acute Viral Hepatitis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACLF</arm_group_label>
    <description>ACLF: Patients with Acute on Chronic Liver Failure</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Acute severe viral hepatitis or acute on chronic liver failure&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient's age 18-70years.&#xD;
&#xD;
          -  Patients with a diagnosis of acute severe viral hepatitis or acute on chronic liver&#xD;
             failure.&#xD;
&#xD;
          -  Patients willing for informed consent and follow up for 1 month.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with gross ascites, hepatic encephalopathy.&#xD;
&#xD;
          -  Patient fail to give written consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anil Arora, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Deptartment of gastroenterology &amp; hepatology, Sir Ganga Ram Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Praveen Sharma, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Gatroenterology &amp; Hepatology, Sir Gnaga Ram Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Praveen Sharma, M.D</last_name>
    <phone>091-9540951004</phone>
    <email>drpraveen_sharma@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anil Arora, M.D</last_name>
    <phone>091-9311638779</phone>
    <email>dranilarora50@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Gastroenterology &amp; Hepatology, Sir Ganga Ram Hospital</name>
      <address>
        <city>New Delhi</city>
        <zip>110060</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Praveen Sharma, M.D</last_name>
      <phone>091-9540951004</phone>
      <email>drpraveen_sharma@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Anil Arora, M.D</last_name>
      <phone>091-9311638779</phone>
      <email>dranilarora50@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Anil Arora, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Praveen Sharma, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <reference>
    <citation>Roulot D, Czernichow S, Le Clésiau H, Costes JL, Vergnaud AC, Beaugrand M. Liver stiffness values in apparently healthy subjects: influence of gender and metabolic syndrome. J Hepatol. 2008 Apr;48(4):606-13. doi: 10.1016/j.jhep.2007.11.020. Epub 2008 Jan 3.</citation>
    <PMID>18222014</PMID>
  </reference>
  <reference>
    <citation>Kumar M, Sharma P, Garg H, Kumar R, Bhatia V, Sarin SK. Transient elastographic evaluation in adult subjects without overt liver disease: influence of alanine aminotransferase levels. J Gastroenterol Hepatol. 2011 Aug;26(8):1318-25. doi: 10.1111/j.1440-1746.2011.06736.x.</citation>
    <PMID>21443658</PMID>
  </reference>
  <reference>
    <citation>de Lédinghen V, Vergniol J. Transient elastography for the diagnosis of liver fibrosis. Expert Rev Med Devices. 2010 Nov;7(6):811-23. doi: 10.1586/erd.10.46.</citation>
    <PMID>21050091</PMID>
  </reference>
  <reference>
    <citation>Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol. 2008 May;48(5):835-47. doi: 10.1016/j.jhep.2008.02.008. Epub 2008 Feb 26. Review.</citation>
    <PMID>18334275</PMID>
  </reference>
  <reference>
    <citation>Garg H, Kumar A, Garg V, Sharma P, Sharma BC, Sarin SK. Clinical profile and predictors of mortality in patients of acute-on-chronic liver failure. Dig Liver Dis. 2012 Feb;44(2):166-71. doi: 10.1016/j.dld.2011.08.029. Epub 2011 Oct 5.</citation>
    <PMID>21978580</PMID>
  </reference>
  <reference>
    <citation>McDONOUGH PG, Tho PT, Byrd JR. Twins discordant for 46,XX gonadal dysgenesis. Fertil Steril. 1977 Mar;28(3):251-2.</citation>
    <PMID>557003</PMID>
  </reference>
  <reference>
    <citation>Arena U, Vizzutti F, Corti G, Ambu S, Stasi C, Bresci S, Moscarella S, Boddi V, Petrarca A, Laffi G, Marra F, Pinzani M. Acute viral hepatitis increases liver stiffness values measured by transient elastography. Hepatology. 2008 Feb;47(2):380-4.</citation>
    <PMID>18095306</PMID>
  </reference>
  <reference>
    <citation>Kumar M, Satapathy S, Monga R, Das K, Hissar S, Pande C, Sharma BC, Sarin SK. A randomized controlled trial of lamivudine to treat acute hepatitis B. Hepatology. 2007 Jan;45(1):97-101.</citation>
    <PMID>17187417</PMID>
  </reference>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>May 28, 2013</study_first_submitted>
  <study_first_submitted_qc>May 30, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 31, 2013</study_first_posted>
  <last_update_submitted>June 3, 2013</last_update_submitted>
  <last_update_submitted_qc>June 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sir Ganga Ram Hospital</investigator_affiliation>
    <investigator_full_name>Dr. Praveen Shrama</investigator_full_name>
    <investigator_title>Associate professor &amp; Consultant</investigator_title>
  </responsible_party>
  <keyword>ACLF</keyword>
  <keyword>AVH</keyword>
  <keyword>Fibroscan</keyword>
  <keyword>Transient elastography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Liver Failure</mesh_term>
    <mesh_term>Hepatic Insufficiency</mesh_term>
    <mesh_term>End Stage Liver Disease</mesh_term>
    <mesh_term>Acute-On-Chronic Liver Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

